INDUSTRY NEWS
Japanese Pharmaceutical Market Value Edging Towards $80 Billion by 2020, says GlobalData
Japan’s pharmaceutical market value is set to grow at a compound annual growth rate (CAGR) of 1.3% from $72.8 billion in 2013 to reach $79.8 billion by 2020, driven by new product launches and the healthcare burden of the country’s aging population, according to research and consulting firm GlobalData. However, the company’s latest report states that the Japanese government’s promotion of generic drugs, its biennial pricing review system, and the depreciation of the yen against the dollar will be limiting factors in what is the second largest mature pharmaceutical market in the world by value.
The market was valued at $64.2 billion in 2008 and peaked at $88 billion in 2011, before a slight dip to $87.2 billion in 2012. A substantial drop in 2013 saw its value decrease by over $14 billion, but GlobalData expects a steady period of recovery to follow.
Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, said: “Deregulation measures introduced in April 2005 have had an impact on overall market performance and more efficient drug reviews have facilitated the entry of new products.
“The approval process has now caught up with that outside of Japan, as highlighted by two approvals for Bristol-Myers Squibb, the Daklinza (daclatasvir) and Sunvepra (asunaprevir) dual regimen for hepatitis C, and Opdivo (nivolumab) for melanoma, prior to their approval by the US Food and Drug Administration.”
Aside from wider economic factors, such as currency exchange rates, GlobalData states that increased use of generic drugs will be a key contributor to the forthcoming period of slow growth to 2020.
Owide continued: “In 2008, generics accounted for 19% of the pharmaceutical space in terms of volume, rising to 25.2% in 2013. Japan has set a goal for generics to account for 60% of all drug use by 2017.
“To this end, the Ministry of Health, Labor and Welfare announced new price cuts in 2013 for drugs with generic replacement of less than 60%, a move which is likely to limit future growth in the pharmaceutical arena.”
3C! Packaging’s Innovation & Serialization Pavilion Debuts at Interphex 2015
3C! Packaging, an independent, privately owned pharmaceutical packaging solutions company specializing in the design and manufacture of custom folding cartons, printed literature, inserts/ outserts, labels/foils, and unit dose applications, will premiere a sophisticated new coating for coding applications at INTERPHEX NYC 2015, April 21–23, at the Jacob K. Javits Center. Offering high precision, functionality, and consistency without intruding upon limited design and product information space, the company’s Clear Code will be showcased at INTERPHEX on a Domino AmJet printer in conjunction with co-developer DataLase.
Clear Code is a next-generation system employing an industrial CO2 laser, which works with a clear coating by causing a color change
reaction to produce a positive contrast image. The result is enhanced
clarity and contrast. The Clear Code process offers 2 significant improvements over traditional coding and competing clear laser etching applications. First, Clear Code avoids marking techniques that require printed dark blocks to decode laser etched information. Second, the process successfully achieves an especially accurate, opaque image. As such, the Clear Code process requires no inks, ribbons, applicators, or other costly consumables, simplifying the process and making it more cost-effective and eco-friendly than current technologies that utilize hazardous production line materials.
At INTERPHEX, 3C! Packaging professionals will be available to share technical expertise regarding this new technology, as well as a set of other innovations on display at the show. These include:
3C! Packaging’s comprehensive portfolio of multiplex cartons run the gamut from traditional and innovative inset-to-carton solutions to label applications and more. 3C!’s Innovation Team has the capabilities needed to give customers any combination of packaging products desired.
3C! Packaging’s new 294-panel outserts provide a significant increase in copy space for necessary product information and instructions. These outserts are, on average, 20% thinner than traditional outserts, leading to a sleeker product appearance and customer savings on production, storage, and shipping costs.
3C! Packaging recently introduced enhanced printed foil lidding for blisters, as well as printed foils with extruded plastics for sachets. By integrating into its operations a cutting-edge 13” FB-3300, 6 color Servo Flexo Press from Nilpeter, 3C! Packaging is running a broad range of multi-substrate packaging materials while specializing in thin-gauged films.
CRF Health Announces Global Partnership with Vodafone
CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, announced a new partnership with Vodafone. CRF Health will use Vodafone’s global Machine-to-Machine (M2M) platform to offer an enhanced service to clinical trial operators and their patients.
As a result of the partnership, managing mobile data sending in clinical studies using the TrialMax® eCOA platform is made significantly easier and more predictable for CRF Health clients. The agreement provides clinical trial sponsors running global studies with assured connectivity and instant access to data through Vodafone’s global network. Reliability, security, and integration are crucial to ensure that healthcare industry requirements and standards are met.
“Having a trusted communications services partner is critical for us," commented CRF Health’s Vice President of Contracts and Vendor Management, Jaime Racine. She continued, "Partnering with Vodafone will help us provide our clients with more predictable data sending while improving the quality of our products and services.”
Vodafone Group’s Head of Machine-to-Machine Sales for Northern Europe, Cyril Deschanel, said, “Our global M2M platform and services
Pharmaceutical Outsourcing | 62 | March/April 2015
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78